Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning()

Neoadjuvant treatment (NAT) has become an option in early stage (stage I-II) breast cancer (EBC). New advances in systemic and targeted therapies have increased rates of pathologic complete response increasing the number of patients undergoing NAT. Clear benefits of NAT are downstaging the tumor and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio, Isabel T., Sobrido, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097809/
https://www.ncbi.nlm.nih.gov/pubmed/34996668
http://dx.doi.org/10.1016/j.breast.2021.12.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097809/
https://www.ncbi.nlm.nih.gov/pubmed/34996668
http://dx.doi.org/10.1016/j.breast.2021.12.019

Ejemplares similares